ePAG visit at Motol University Hospital in Prague

Like every year our ePAGs visit one of our expert centers to learn more about their work and how they organize care for patients with rare neurological diseases. This year, on 4 June 2026, seven of us — along with our project manager and communications manager — found ourselves in the beautiful city of Prague at Motol University Hospital. This visit was made possible through Julie Nováková Martínková, ERN-RND Disease Group coordinator for Frontotemporal Dementia (FTD) and clinician at Motol as well as Martin Vyhnalek, associate professor at Motol, who generously helped organize the exchange. What impressed us most was the excellent national awareness of this center: They educate neurologists across the country, enabling rapid expert consultation—within just two months. The pediatric and adult teams meet regularly, ensuring a smooth transition to adult care.

As patient representatives in ERN-RND, our main objective was to understand how ERN membership integrates into their clinical practice.

Motol is the only national reference center for ataxias and HSPs (Hereditary Spastic Paraplegias) in the Czech Republic, actively following more than 500 patients with these conditions. They also serve as one of three national expert centers for FTD. Notably, they have introduced a new Care Coordinator role that bridges the expert center with local facilities—a model that strengthens their reach and improves continuity of care.

The meeting began with a comprehensive presentation from the hospital team, followed by a tour of the laboratory and neurology department, where we learned about the diagnostic tools they use for early detection, enabling faster and more accurate diagnoses.

The most engaging and memorable part of our visit was an interactive session with the speech therapists, whose role in neurology is critical. They explained that their work extends far beyond speech to include non-verbal communication and dysphagia management. They demonstrated practical exercises used with patients, inviting us to participate. We blew bubbles to strengthen our vocal cords and practiced the Mendelsohn and Masako maneuvers—targeted swallowing exercises designed to strengthen throat muscles, improve coordination, and prevent aspiration. This hands-on experience gave us profound insight into the daily work of rehabilitation and the dedication required to support patients with these conditions.

In attendance were hospital clinicians and two patient representatives: Tomáš Pick, representing ataxia patients, and Jakub Šunek, who is in the early stages of developing the first HSP patient organization in the Czech Republic. Their inclusion demonstrates this center’s genuine commitment to patient-centered care and collaborative decision-making—a sign that they truly care about and are invested in helping their patients.

Particularly exciting is the opportunity to continue working with Jakub. As an advisor to EuroHSP, I will be connecting him with the organization as he builds the Czech HSP patient community. This collaboration could significantly strengthen support for HSP patients in the region and represents the kind of international partnership that ERN membership enables.

The team identified important opportunities for improvement. A critical barrier emerged: lack of awareness among policymakers and healthcare systems about rare diseases and what specialized care they require. Without this foundational understanding, ERN expertise and the time-intensive consultations that save lives remain undervalued and underfunded. With sustainable support for ERN activities and better recognition of these complex consultations, they would be able to expand their team and hire additional coordinators and administrative staff.

Yet our dialogue confirmed what became clear throughout the visit: we share common goals. We work on the same challenges from different perspectives—challenges that ultimately require the attention of politicians and governmental departments. This visit reinforced that patient voices, clinical expertise, and policy advocacy must work together to create real change for people living with rare neurological diseases.

Lori Renna Linton (collaborative writing with the ePAGs)

ERNs Flagship Manuscript Published

The European Reference Network (ERN) flagship manuscript has just been published in the Orphanet Journal for Rare Disease. The manuscript provides an overview of what ERNs are, what they deliver and what they aim to become.

Short summary
Although each rare and complex disease affects relatively few people, together they impact an estimated 27–36 million people in the European Union. To address this major public health challenge, the EU established the European Reference Networks (ERNs) in 2017. ERNs connect expert centres across borders to improve and harmonise diagnosis and care for patients with rare and complex diseases. Today, 24 ERNs link 1,606 expert centres in 375 hospitals across all EU Member States and Norway. Their work includes multidisciplinary case discussions, education, guideline development, and patient-centred governance. More than 4,900 highly complex cases have been reviewed without requiring patients to travel abroad, supported by the European Commission’s secure Clinical Patient Management System 2.0. ERNs also proved resilient during the COVID-19 pandemic and the war in Ukraine. A 2023 evaluation found that over 95% of member centres met quality standards. The Joint Action JARDIN (2024–2027) now seeks to embed ERNs into national health systems to ensure sustainable and equitable access to high-quality rare disease care.

Declaration on the European Innovation and Care Ecosystem for Rare and Complex Diseases

Last December’s High Level Meeting on a European Innovation and Care Ecosystem for Rare and Complex Diseases brought together policymakers, researchers, healthcare professionals, industry and the patient advocacy to help shape the future of rare disease policy in Europe.

This collective effort culminated in the Declaration on the EU Innovation and Care Ecosystem for Rare and Complex Diseases—a bold commitment to building a sustainable research and innovation ecosystem, supported by dedicated funding.

We, alongside many other European Reference Networks, have signed this Declaration and will actively work towards advancing its goals within our remit.

Find the Declaration here. More information here.

Holm Graessner at the Brain Innovation Days 2025

Our coordinator Holm Graessner is participating in the Brain Innovation Days’ Platinum Panel “Advancing Adaptive Pathways and Real-World Evidence for Orphan Drugs” on October 15th, 11:55 CEST.

This session will explore how adaptive pathways and Real-World Evidence (RWE), including patient-experienced data, can be more effectively integrated into policy frameworks to improve access to innovative treatments for rare brain disorders. With patients often facing long delays and limited options, there is a growing need to rethink how we evaluate and approve therapies. In partnership with Merck KGaA Healthcare, this session will bring together stakeholders from across the healthcare ecosystem and aims to identify collaborative, patient-centred policy solutions that accelerate access while ensuring long-term sustainability and equity.

Find the whole programme here.

Meet us at EAN2025

Are you at this year’s EAN Congress in Helsinki? Then come and visit us at our booth (N21) in the Neurohood and have a coffee with us – the ERNs EURO-NMD, epiCARE and EFNA, the European umbrella organisation of neurological patient advocacy groups, will also be there!

Please find below our contributions.

—– SUNDAY 22 June —–

16:25 – 16:55 EEST

ERN-RND: Improving care for rare neurological diseases: The European reference networks

—– MONDAY 23 June —–

16:25 – 16:55 EEST

ERN-RND: Current practices regarding genetic therapies in Europe

Conference: Towards an EU Action Plan on Rare Diseases

What is the use of Patient Registries? And how does data sharing in the ERNs work? Our coordinator Holm Graessner will give an insight on this at the EESC Conference “Towards an EU Action Plan on Rare Diseases” on April 10, 16:30 CEST.

And our patient advocate Lori Renna Linton will talk about Patient Journeys and how to develop one, at 12:00 CEST.

You can now register for online participation here. Find the programme here.

Find the recordings here. Holm Graessner’s talk starts at 7:46:00, Lori Renna Linton’s talk at 2:35:00.

Meeting with MEPs for Rare Disease Day

Rare Disease Day is coming up! Join us for shaping the future on policy for Rare Neurological Diseases on February 19, 10-12 CET. Join the meeting with the MEP Interest Group Brain Helath & Neurological Conditions together with our coordinator Holm Graessner as panelist.

Big thanks to the European Federation of Neurological Associations (EFNA) for this invitation! To participate on-site or online please register till February 5: https://www.efna.net/mep-february25/

6th ERN-RND Winter School

The European Pediatric Neurology Society (EPNS) and the European Reference Network for Rare Neurological Diseases (ERN-RND) are organizing a Winter School on Challenges of Treating Rare Neurological Diseases.

The school will take place virtually, from 12th to 14th March 2025.

Day 1 Disease Modifying Therapies
Day 2 Movement Disorders
Day 3 Co-morbidities and Cases

Find the programme here.

Registration